October 25, 2021
The Effect of Evobrutinib, a Brutons Tyrosine Kinase Inhibitor, on Blood Neurofilament Light Chain Levels in Relapsing Multiple Sclerosis
Background: Evobrutinib is a highly selective Brutons tyrosine kinase inhibitor targeting B cells and myeloid cells. A phase 2 randomized...
Poster-Disease-modifying Therapy
October 25, 2021
Baseline MRI Predictors of Cognitive Processing Speed in Participants with Secondary Progressive Multiple Sclerosis from the Phase 3 Expand Study
Background: Siponimod showed beneficial effects on magnetic resonance imaging (MRI) lesion activity, total brain and gray matter (GM)...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years
Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Efficacy and Safety of Siponimod in Active SPMS and Overall SPMS Populations: Expand Study Data up to 5 Years
Background: In the EXPAND Core study, siponimod significantly reduced the risk of 3-/6-months(m) confirmed disability progression...